Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

by Ohe, Yuichiro , Cho, Byoung Chul , Gray, Jhanelle E , Kurata, Takayasu , Cheng, Ying , John, Thomas , Lin, Meng-Chih , Soria, Jean-Charles , Rukazenkov, Yuri , Ramalingam, Suresh S , Cheema, Parneet , Chewaskulyong, Busyamas , Zhou, Caicun , Tiseo, Marcello , Todd, Alexander , Reungwetwattana, Thanyanan , Shah, Riyaz , Imamura, Fumio , Planchard, David , Cobo, Manuel , Lee, Ki Hyeong , Saggese, Matilde , Vansteenkiste, Johan , Hodge, Rachel

in Acrylamides - adverse effects / Acrylamides - therapeutic use / Aged / Aniline Compounds - adverse effects / Aniline Compounds - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Cancer / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Clinical medicine / Clonal deletion / Confidence intervals / Double-Blind Method / Drug dosages / Enzyme inhibitors / Epidermal growth factor / Epidermal growth factor receptors / ErbB Receptors - antagonists & inhibitors / ErbB Receptors - genetics / Erlotinib Hydrochloride - therapeutic use / Female / Gefitinib / Gefitinib - therapeutic use / Gene deletion / Humans / Inhibitor drugs / Kaplan-Meier Estimate / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Male / Metastasis / Middle Aged / Mutation / Non-small cell lung carcinoma / Proportional Hazards Models / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Protein-tyrosine kinase / Small cell lung carcinoma / Statistical analysis / Targeted cancer therapy / Tumors

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2020

Confirm

Do you wish to request the book?

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Ohe, Yuichiro,

Cho, Byoung Chul,

Gray, Jhanelle E,

Kurata, Takayasu,

Cheng, Ying,

John, Thomas,

Lin, Meng-Chih,

Soria, Jean-Charles,

Rukazenkov, Yuri,

Ramalingam, Suresh S,

Cheema, Parneet,

Chewaskulyong, Busyamas,

Zhou, Caicun,

Tiseo, Marcello,

Todd, Alexander,

Reungwetwattana, Thanyanan,

Shah, Riyaz,

Imamura, Fumio,

Planchard, David,

Cobo, Manuel,

Lee, Ki Hyeong,

Saggese, Matilde,

Vansteenkiste, Johan,

Hodge, Rachel

2020

Overview

Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall survival was 38.6 months with osimertinib and 31.8 months with erlotinib or gefitinib. This 20% lower risk of death was noted despite the crossover of patients from standard therapy to osimertinib during subsequent therapy.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acrylamides - adverse effects

/ Acrylamides - therapeutic use

/ Aged

/ Aniline Compounds - adverse effects

/ Aniline Compounds - therapeutic use

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use